FCM
VKTX icon

Fieldview Capital Management’s Viking Therapeutics VKTX Stock Holding History

Fieldview Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,483
Closed -$211K – 728
2026
Q1 		$211K Buy
+6,483
New +$208K 0.06% 444
2025
Q1 		– Sell
-37,013
Closed -$1.49M – 601
2024
Q4 		$1.49M Buy
+37,013
New +$2.11M 0.23% 131

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Fieldview Capital Management's VKTX Position: Q2 2026 in Review

Fieldview Capital Management sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 6,483 shares — an estimated $211K sold.

Fieldview Capital Management first reported a position in VKTX in Q4 2024 and held it in 2 quarters. The position peaked at $1.49M in Q4 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Fieldview Capital Management reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fieldview Capital Management sold 6,483 Viking Therapeutics shares in Q2 2026, an estimated $211K.
  • Fieldview Capital Management first reported a position in Viking Therapeutics in Q4 2024 and held it in 2 quarters.
  • Fieldview Capital Management's Viking Therapeutics position peaked at $1.49M in Q4 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Fieldview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.